Literature DB >> 1710892

Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I.

F M Tomas1, S E Knowles, P C Owens, L C Read, C S Chandler, S E Gargosky, F J Ballard.   

Abstract

We have examined the effects of infusing recombinant human growth hormone (hGH), insulin-like growth factor-I (IGF-I), the truncated IGF-I analogue, des(1-3)IGF-I, and insulin over a 7-day period in streptozotocin-induced diabetic rats. IGF-I at a dose of 1.05 or 1.08 mg/kg per day in two experiments increased body weight and nitrogen retention above those of vehicle-infused controls to about 30% of the improvement achieved with 25 or 30 units of insulin/kg per day, but only in the second experiment were the differences statistically significant (P less than 0.05). A 2.5-fold higher IGF-I dose, or des(1-3)IGF-I at 1.08 mg/kg per day, gave effects that were approx. 70% of those obtained with insulin. hGH at 1.38 mg/kg per day was not effective. The IGF peptides, unlike insulin, did not ameliorate the diabetic glucosuria. The improvements in nitrogen balance could be accounted for in part by increases in muscle protein synthesis. Muscle protein breakdown, as assessed by 3-methylhistidine excretion, was inhibited by insulin, but not by the IGF peptides. Carcass fat increased substantially following insulin administration. This did not occur with the IGF peptides, suggesting that IGF predominantly stimulates the growth of lean tissue. IGF-I concentrations and IGF-I-binding proteins in plasma were increased by IGF-I, especially at the higher dose, whereas hGH produced only a transient increase in IGF-I. Des(1-3)IGF-I induced binding proteins, but had only a slight effect on measured IGF-I concentrations. We conclude that IGF peptides stimulate muscle protein synthesis and improve nitrogen balance in diabetes without obviously influencing the abnormal carbohydrate metabolism. Moreover, des(1-3)IGF-I is at least as potent as the full-length IGF-I.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710892      PMCID: PMC1151126          DOI: 10.1042/bj2760547

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies.

Authors:  P Hossenlopp; D Seurin; B Segovia-Quinson; S Hardouin; M Binoux
Journal:  Anal Biochem       Date:  1986-04       Impact factor: 3.365

2.  On the nomenclature of the IGF binding proteins.

Authors:  J Ballard; R Baxter; M Binoux; D Clemmons; S Drop; K Hall; R Hintz; M Rechler; E Rutanen; J Schwander
Journal:  Acta Endocrinol (Copenh)       Date:  1989-11

3.  Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.

Authors:  M Ross; G L Francis; L Szabo; J C Wallace; F J Ballard
Journal:  Biochem J       Date:  1989-02-15       Impact factor: 3.857

4.  Studies of the diabetogenic action of streptozotocin.

Authors:  A Junod; A E Lambert; L Orci; R Pictet; A E Gonet; A E Renold
Journal:  Proc Soc Exp Biol Med       Date:  1967-10

5.  Skeletal muscle proteolysis in rats with acute streptozocin-induced diabetes.

Authors:  O L Smith; C Y Wong; R A Gelfand
Journal:  Diabetes       Date:  1989-09       Impact factor: 9.461

6.  Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E Futo; H Häsler; K Binz; H P Guler; C Schmid; E R Froesch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Regulation of hepatic expression of IGF I and fetal IGF binding protein mRNA in streptozotocin-diabetic rats.

Authors:  M Böni-Schnetzler; K Binz; J L Mary; C Schmid; J Schwander; E R Froesch
Journal:  FEBS Lett       Date:  1989-07-17       Impact factor: 4.124

8.  Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I.

Authors:  E Scheiwiller; H P Guler; J Merryweather; C Scandella; W Maerki; J Zapf; E R Froesch
Journal:  Nature       Date:  1986 Sep 11-17       Impact factor: 49.962

9.  Growth hormone and growth in diabetic rats: effects of insulin and insulin-like growth factor-I infusions.

Authors:  L M Carlsson; R G Clark; A Skottner; I C Robinson
Journal:  J Endocrinol       Date:  1989-09       Impact factor: 4.286

10.  Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin.

Authors:  R Jacob; E Barrett; G Plewe; K D Fagin; R S Sherwin
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

View more
  11 in total

1.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.

Authors:  Jie Du; Xiaonan Wang; Christiane Miereles; James L Bailey; Richard Debigare; Bin Zheng; S Russ Price; William E Mitch
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

2.  Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis.

Authors:  Ashis K Samanta; Valeria A Torok; Nigel J Percy; Suzanne M Abimosleh; Gordon S Howarth
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

3.  Grape seed extract reduces the severity of selected disease markers in the proximal colon of dextran sulphate sodium-induced colitis in rats.

Authors:  Ker Y Cheah; Susan E P Bastian; Thomas M V Acott; Suzanne M Abimosleh; Kerry A Lymn; Gordon S Howarth
Journal:  Dig Dis Sci       Date:  2012-11-10       Impact factor: 3.199

4.  Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.

Authors:  F M Tomas; S E Knowles; P C Owens; C S Chandler; G L Francis; F J Ballard
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

5.  Colonic absorption of insulin-like growth factor I in vitro.

Authors:  E Quadros; N M Landzert; S LeRoy; F Gasparini; G Worosila
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

6.  Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.

Authors:  F M Tomas; S E Knowles; P C Owens; C S Chandler; G L Francis; L C Read; F J Ballard
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

7.  Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.

Authors:  F M Tomas; C S Chandler; P Coyle; C S Bourgeois; J L Burgoyne; A M Rofe
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

8.  Local insulin-like growth factor I prevents sepsis-induced muscle atrophy.

Authors:  Gerald Nystrom; Anne Pruznak; Danuta Huber; Robert A Frost; Charles H Lang
Journal:  Metabolism       Date:  2009-06       Impact factor: 8.694

9.  Metabolic response of sheep skin to a chronic infusion of a variant of insulin-like growth factor I.

Authors:  J E Hocking Edwards; S K Khalaf; B R Sinclaire; J Lee; C G Prosser; P M Harris
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

10.  Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy.

Authors:  Rasha Kamil; Mark S Geier; Ross N Butler; Gordon S Howarth
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.